Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6-Induced Experimental Prostate Cancer Metastases Formation

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-13-0605
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

FRI0428 the JAK1-selective Inhibitor, Filgotinib, Inhibits Inflammation Pathways Observed in an IL23-induced Psoriatic Arthritis Mouse Model

2017English

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade

Cancer immunology research
Cancer ResearchImmunology
2016English

Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

IL-6 Inhibits Starvation-Induced Autophagy via the STAT3/Bcl-2 Signaling Pathway

Scientific Reports
Multidisciplinary
2015English

Role of the IL-6-JAK1-STAT3-Oct-4 Pathway in the Conversion of Non-Stem Cancer Cells Into Cancer Stem-Like Cells

Cellular Signalling
Cell Biology
2013English

Matrine Increases the Inhibitory Effects of Afatinib on H1975 Cells via the IL-6/JAK1/STAT3 Signaling Pathway

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2017English

Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

2007English

HOXA10 Deteriorates Gastric Cancer Through Activating JAK1/STAT3 Signaling Pathway

Cancer Management and Research
Oncology
2019English

Thymic Stromal Lymphopoietin-Mediated STAT5 Phosphorylation via Kinases JAK1 and JAK2 Reveals a Key Difference From IL-7-induced Signaling

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy